STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the opening of its new Canadian sales office at the MaRS Centre in downtown Toronto, Ontario.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026694197/en/

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the opening of its new Canadian sales office at the MaRS Centre, located in the heart of downtown Toronto’s Discovery District. (Photo: Business Wire)

“The opening of our new Toronto base marks a major milestone in STEMCELL’s 30-year history and is a testament to our growing presence in North America,” said Dr. Allen Eaves, President and CEO, STEMCELL. “This facility will enable us to strengthen ties in the Toronto area and better support the scientists in both academia and industry who are doing great work here.”

Located in the city’s Discovery District, the MaRS Centre is North America’s largest urban innovation hub. Consisting of over 1.5 million square feet, it hosts a curated roster of more than 120 tenants, including globally recognized research labs, tech corporates, capital providers, and many of Canada’s most promising health and life sciences startups. STEMCELL will take up occupancy at MaRS' West Tower, a LEED Gold building, at 661 University Avenue.

“As a company of Scientist Helping Scientists, STEMCELL is looking forward to being part of the MaRS community and collaborating with leading principal investigators to tackle some of the biggest challenges of our time,” said Dr. Eaves.

Headquartered in Vancouver, British Columbia, STEMCELL has a global presence, with offices in eight countries: Canada, United States, United Kingdom, France, Germany, China, South Korea, and Singapore. In total, STEMCELL has sales staff in 20 countries and distributors in 80 other countries. Of its 2400 global employees, 1800 are based in Canada.

STEMCELL’s connection with MaRS began when the company commissioned bronze portraits of Drs. James Till and Ernest McCulloch—considered the pioneers of stem cell research—by artist Ruth Abernethy. Unveiled in 2017, the sculpture was donated to MaRS by STEMCELL and today sits outside the MaRS Centre entrance. A sister sculpture can be found in front of Vancouver’s Science World near STEMCELL’s head office.

“As a PhD student, I was honored to study under Drs. Till and McCulloch, and so the opening of this office at MaRS close to the University of Toronto is especially meaningful for me,” said Dr. Eaves. “This is where it all began for stem cell research and where, in large part thanks to Drs. Till and McCulloch, my own career in this area of science started. It is important to me that STEMCELL continues to build on their legacy and make big contributions to the science, biotech, and innovation ecosystem here in Toronto and beyond.”

More information about the MaRS Centre can be found by visiting https://www.marsdd.com.

About STEMCELL Technologies

STEMCELL Technologies supports life sciences research with more than 2500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231026694197/en/

For more information and to arrange an interview, contact:
Ryan-Sang Lee
Senior Manager, Corporate Communications, STEMCELL Technologies
public.relations@stemcell.com

Logo

Images

Tags

More Like This

STEMCELL Technologies Releases “Toward Sustainable Science” Report

STEMCELL Technologies Wins a Canada’s Most Admired Corporate Cultures™ of 2023 Award

STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company

STEMCELL Technologies Announces Acquisition of Propagenix Inc.

Merck Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour

C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products

The Largest Biotech City in Europe Will Soon Be Built, With an Investment Amounting to 7 Billion Euros

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center